Strides Shasun’s wholly owned subsidiary -- Strides Pharma Global has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (USFDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.
According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately $20 million. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma in the US Market. The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.
Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has 74 cumulative ANDA filings with USFDA of which 45 ANDAs have been approved as of date and 29 are pending approval.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: